Cellares and Ori Biotech Lead Automated Cell Therapy Production Market with FDA Advanced Manufacturing Technology Designation

June 20, 2026

Fierce Pharma USA

Overview

A Tracxn report highlights Cellares and Ori Biotech as dominant leaders in automated cell therapy production, both holding FDA’s Advanced Manufacturing Technology (AMT) designation. Their closed systems aim to mitigate high costs, labor intensity, and up to 18% batch failure rates of conventional methods. Given the substantial pipeline of cell therapies, existing capacity is projected to be insufficient, positioning automated solutions as critical for resolving industry bottlenecks and scaling production.

In Depth

Key Findings

According to a recent report by Tracxn, Cellares and Ori Biotech are emerging as the dominant leaders in the automated cell therapy production market. Both companies have received the U.S. Food and Drug Administration’s (FDA) Advanced Manufacturing Technology (AMT) designation, underscoring their innovative prowess. Their proprietary closed systems are specifically designed to tackle critical challenges in cell therapy manufacturing, including exorbitant costs, labor-intensive processes, and alarmingly high batch failure rates that can reach up to 18%.

Technical / Clinical Details

FDA AMT Designation Significance: The FDA’s AMT designation recognizes technologies that promise significant advancements in pharmaceutical manufacturing efficiency and quality. This designation signals that Cellares and Ori Biotech are at the forefront of developing next-generation manufacturing solutions, validating their technical superiority and regulatory compliance.
Advantages of Closed Systems: Both companies employ closed-system platforms for their automated manufacturing processes. This design substantially reduces the risk of external contamination, thereby enhancing product safety and maintaining consistent quality. Furthermore, minimal human intervention translates to reduced operational burden and increased process reliability.
Addressing Manufacturing Challenges: Traditional cell therapy manufacturing often relies on highly skilled personnel performing manual steps, leading to high costs, extended timelines, and a reported batch failure rate of up to 18%. Cellares and Ori Biotech’s automation technologies directly address these issues by standardizing processes, reducing costs, and increasing throughput.
Market Demand vs. Capacity: The current cell therapy pipeline is robust, with a multitude of candidates progressing towards approval. This anticipated surge in approved therapies is expected to significantly strain existing manufacturing capacities. Automated production systems are therefore crucial for bridging this impending manufacturing bottleneck and enabling widespread patient access.

Background & Context

While cell and gene therapies represent a revolution in treating cancers and rare diseases, their commercialization and broad patient access have been hindered by inherent manufacturing challenges. The complexity of production, the high cost associated with personalized therapies, and the lack of scalability have been major industry-wide barriers. Automated manufacturing technologies are positioned as central solutions to dismantle these barriers, making cell therapies more accessible and cost-effective.

Strategic Significance & Outlook

The leadership of Cellares and Ori Biotech in automated cell therapy production marks a significant shift in the industry’s manufacturing paradigm. As their technologies gain wider adoption, production costs for cell therapy products are expected to decrease, and manufacturing lead times will shorten. Ultimately, this will enable more patients to access these transformative treatments. The FDA’s AMT designation highlights the regulatory recognition of these technologies, indicating that automated manufacturing platforms are likely to become the standard in the cell and gene therapy sector. This evolution is an indispensable element for accelerating the industry’s growth and maturation, ensuring that life-changing therapies reach those who need them most.

Source: https://www.fiercepharma.com/manufacturing/cellares-ori-reign-supreme-automated-cell-therapy-manufacturing-advances-report

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.